Non-ICANS Neurotoxicity After CAR-T Therapy: Real-World Surveillance and Management in Multiple Myeloma

The Surveillance Playbook: Mapping Non-ICANS Neurotoxicity in Real-World CAR-T Care 

How Real-World Data Is Improving the Detection and Management of Delayed Neurotoxicity After BCMA CAR-T Therapy

The introduction of B-cell maturation antigen (BCMA)-directed Chimeric Antigen Receptor T-cell (CAR-T) therapies, particularly ciltacabtagene autoleucel (cilta-cel), has transformed treatment outcomes for patients with relapsed or refractory multiple myeloma (RRMM). While these therapies deliver durable remissions, clinicians are increasingly focused on optimizing long-term safety.

Although Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) are well-recognized and routinely monitored, attention is now shifting toward delayed non-ICANS neurologic events (NEs). Supported by real-world evidence, healthcare teams are adopting biomarker-driven surveillance strategies to identify these rare complications early and improve patient outcomes.

Understanding Non-ICANS Neurotoxicity After CAR-T Therapy

What Are Non-ICANS Neurologic Events?

Unlike acute ICANS, non-ICANS neurologic events occur weeks or even months after CAR-T infusion.

Common delayed neurologic complications include:

• Cranial nerve palsy (CNP)
• Immune effector cell (IEC)-associated parkinsonism
• Guillain–Barré syndrome (GBS)
• Peripheral neuropathies

These events are uncommon but require extended monitoring beyond the standard post-infusion observation period.

Real-World Evidence Shows Low Incidence

Reassuring Safety Data for Cilta-cel

Large real-world databases indicate that delayed neurotoxicity remains rare and manageable, with incidence rates generally lower than those reported in early clinical trials.

Patients with 1–3 Prior Lines of Therapy

Among early-relapse patients:

• Cranial nerve palsy occurs in approximately 5.1–5.6%
• Median onset is 22–26 days after infusion
• No reported cases of IEC-parkinsonism or GBS in major observational cohorts

Patients with ≥4 Prior Lines of Therapy

For heavily pre-treated patients:

• IEC-associated parkinsonism: ~1.0%
• Cranial nerve palsy: 1.0–4.6%
• Guillain–Barré syndrome: 0.2–0.5%

Most patients recover with timely intervention, and these neurologic events generally do not reduce the anti-myeloma efficacy of CAR-T therapy.

Peak Absolute Lymphocyte Count: A Practical Biomarker

Why ALC Matters in Neurotoxicity Surveillance

One of the most valuable bedside biomarkers identified through real-world research is the Absolute Lymphocyte Count (ALC) during the early post-infusion expansion phase.

The 3000/µL Threshold

Patients with:

Peak ALC >3000/µL

show a significantly increased risk of delayed neurologic toxicity, particularly IEC-associated parkinsonism.

Patients below this threshold demonstrate a substantially lower risk.

Why Elevated ALC Increases Risk

Higher ALC reflects:

• Rapid CAR-T cell expansion
• Sustained immune activation
• Prolonged neuroinflammation affecting the central and peripheral nervous systems

Routine CBC monitoring therefore becomes an effective and accessible surveillance strategy.

The Role of Bridging Therapy Response

How Pre-Infusion Disease Control Influences Neurotoxicity

Clinical outcomes suggest that failure to respond to bridging therapy before CAR-T infusion significantly increases the likelihood of delayed neurologic complications.

Why It Happens

Poor disease control results in:

• Higher antigen burden
• Greater CAR-T expansion
• Elevated inflammatory activity
• Increased neurotoxicity risk

Successful tumor debulking before lymphodepletion may therefore contribute to safer long-term outcomes.

Monitoring Timeline for Non-ICANS Neurotoxicity

Recommended Surveillance Strategy

Days 0–14

Focus: CRS and acute ICANS

Monitor:

• Cognitive status
• Handwriting changes
• Standard immune toxicity assessments

Days 10–28

Focus: CAR-T expansion

Monitor:

• Daily CBC with differential
• Absolute lymphocyte count trends
• ALC approaching or exceeding 3000/µL

Days 21–45

Focus: Cranial nerve assessment

Evaluate for:

• Facial weakness
• Ptosis
• Diplopia
• Altered taste sensation

Days 30–90+

Focus: Movement disorders and cognitive function

Screen for:

• Resting tremor
• Bradykinesia
• Micrographia
• Rigid gait
• Flat facial expression

Management Strategies for High-Risk Patients

Early Intervention Improves Outcomes

Patients with elevated ALC or poor bridging responses may benefit from closer neurological surveillance.

Current Management Approaches

• Early corticosteroid therapy in selected high-risk patients
• High-dose intravenous methylprednisolone for neurologic events
• Intravenous immunoglobulin (IVIG) or plasmapheresis for Guillain–Barré syndrome
• Long-term caregiver education for delayed symptom recognition

Early recognition remains the most effective strategy for minimizing long-term neurological complications.

The Future of CAR-T Neurotoxicity Surveillance

From Reactive Care to Biomarker-Guided Monitoring

Real-world evidence is shifting CAR-T follow-up from symptom-based observation toward predictive surveillance.

By integrating:

• Peak ALC monitoring
• Bridging therapy response
• Structured neurological assessments
• Extended outpatient follow-up

hemato-oncology teams can detect delayed neurotoxicity earlier while preserving the remarkable therapeutic benefits of BCMA-directed CAR-T therapy.

Conclusion

The growing use of cilta-cel has highlighted the importance of monitoring delayed non-ICANS neurologic events in patients with relapsed or refractory multiple myeloma. Fortunately, real-world studies demonstrate that these complications remain uncommon, manageable, and often less frequent than initially reported in clinical trials.

With biomarker-driven surveillance, multidisciplinary follow-up, and proactive intervention, clinicians can continue delivering highly effective CAR-T therapy while maintaining a strong long-term safety profile.

#CARTTherapy #MultipleMyeloma